UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

Differential activation of the prefrontal cortex and amygdala following psychological stress and colorectal distension in the maternally separated rat

Neuroscience, 2014-05, Vol.267, p.252-262

2014

Volltextzugriff (PDF)

Colorectal distension-induced prefrontal cortex activation in the Wistar–Kyoto rat: implications for irritable bowel syndrome

Neuroscience, 2010-02, Vol.165 (3), p.675-683

2010

Volltextzugriff (PDF)

96. Anti-depressants and kynurenine pathway inhibition: A therapeutic strategy for neuroprotection in vitro ?

Brain, behavior, and immunity, 2013-09, Vol.32, p.e28-e28

2013

Volltextzugriff (PDF)

Interferon-gamma stimulated microglia induce neurotoxicity – A role for the kynurenine pathway?

Brain, behavior, and immunity, 2011, Vol.25, p.S219-S219

2011

Volltextzugriff (PDF)

154. The serotonin transporter and monoamine oxidase A as novel pharmacological targets to inhibit microglial activation

Brain, behavior, and immunity, 2011, Vol.25, p.S223-S223

2011

Volltextzugriff (PDF)

164. The Beta2-adrenoceptor agonist, salbutamol, induces GDNF expression in glia and increases the viability of cortical neurons

Brain, behavior, and immunity, 2011, Vol.25, p.S226-S226

2011

Volltextzugriff (PDF)

AB0186 Elevated Indoleamine-2,3-Dioxygenase (IDO) and Tryptophan Catabolism in Primary SjÖGren's Syndrome Patients, Positive for the Interferon Type I Signature: A Possible Link to Fatigue and Depression

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.864-864

2014

Volltextzugriff (PDF)

Studies on the effects of growth factors on the differentiation and myelination competency of developing oligodendrocytes

Gibney, S.M

2007

Volltextzugriff (PDF)

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

Nature reviews. Clinical oncology, 2013-07, Vol.10 (7), p.390-399

2013

Volltextzugriff (PDF)

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

Oncogene, 2013-06, Vol.32 (25), p.3009-3018

2013

Volltextzugriff (PDF)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

Oncogene, 2016-03, Vol.35 (10), p.1225-1235

2016

Volltextzugriff (PDF)

Beyond BRAF: where next for melanoma therapy?

British journal of cancer, 2015-01, Vol.112 (2), p.217-226

2015

Volltextzugriff (PDF)

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

Cancer discovery, 2015-03, Vol.5 (3), p.264-273

2015

Volltextzugriff (PDF)

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma

Pigment cell and melanoma research, 2014-11, Vol.27 (6), p.1154-1158

2014

Volltextzugriff (PDF)

An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance

Cancer discovery, 2013-03, Vol.3 (3), p.260-263

2013

Volltextzugriff (PDF)

Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics

Molecular & cellular proteomics, 2014-07, Vol.13 (7), p.1844-1854

2014

Volltextzugriff (PDF)

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Clinical cancer research, 2013-11, Vol.19 (22), p.6329-6330

2013

Volltextzugriff (PDF)

Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma

Pigment cell and melanoma research, 2014-05, Vol.27 (3), p.465-478

2014

Volltextzugriff (PDF)

Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma

Clinical cancer research, 2018-11, Vol.24 (22), p.5516-5524

2018

Volltextzugriff (PDF)

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation

Journal of investigative dermatology, 2015-10, Vol.135 (10), p.2542-2544

2015

Volltextzugriff (PDF)

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma

Proteomics (Weinheim), 2015-01, Vol.15 (2-3), p.327-339

2015

Volltextzugriff (PDF)

p110α Contributes to p110δ Inhibitor Resistance

Cancer discovery, 2013-03, Vol.3 (3), p.249-249

2013

Volltextzugriff (PDF)

An unholy alliance: co-operation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance

Cancer discovery, 2013-03, Vol.3 (3), p.260-263

2013

Volltextzugriff (PDF)

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy

Melanoma research, 2016-02, Vol.26 (1), p.83-87

2016

Volltextzugriff (PDF)

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma

Melanoma research, 2017-12, Vol.27 (6), p.545-557

2017

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(31)

Publikationsform

Sprache

Englisch
(35)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(22)
Humans
(20)
Oncology
(12)
Melanoma
(10)
Melanoma - Drug Therapy
(10)
Melanoma - Genetics
(10)
Melanoma - Pathology
(9)
Proto-Oncogene Proteins B-Raf - Genetics
(9)
Animals
(7)
Dermatology
(7)
Gtp Phosphohydrolases - Genetics
(7)
Membrane Proteins - Genetics
(7)
Proto-Oncogene Proteins B-Raf - Antagonists & Inhibitors
(7)
Biological And Medical Sciences
(6)
Cell Line, Tumor
(6)
Female
(6)
Male
(6)
Protein Kinase Inhibitors - Pharmacology
(6)
Mutation
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Differential activation of the prefrontal cortex and amygdala following psychological stress and colorectal distension in the maternally separated rat

Colorectal distension-induced prefrontal cortex activation in the Wistar–Kyoto rat: implications for irritable bowel syndrome

96. Anti-depressants and kynurenine pathway inhibition: A therapeutic strategy for neuroprotection in vitro ?

Interferon-gamma stimulated microglia induce neurotoxicity – A role for the kynurenine pathway?

154. The serotonin transporter and monoamine oxidase A as novel pharmacological targets to inhibit microglial activation

164. The Beta2-adrenoceptor agonist, salbutamol, induces GDNF expression in glia and increases the viability of cortical neurons

AB0186 Elevated Indoleamine-2,3-Dioxygenase (IDO) and Tryptophan Catabolism in Primary SjÖGren's Syndrome Patients, Positive for the Interferon Type I Signature: A Possible Link to Fatigue and Depression

Studies on the effects of growth factors on the differentiation and myelination competency of developing oligodendrocytes

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

Beyond BRAF: where next for melanoma therapy?

Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma

An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance

Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics

Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Letter

Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma

Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation

Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma

p110α Contributes to p110δ Inhibitor Resistance

An unholy alliance: co-operation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma

Suchergebnisse filtern